Personalized precision medicine

• Autorzy: Konieczny Leszek , Roterman Irena

Identyfikatory

DOI

10.1515/bams-2019-0047

• Języki publikacji: EN

Abstrakty

EN

Along with the development of modern science, medical knowledge and therapy become more and more precise and personal as a consequence. Genetics and immunology participate in the progress in particular. They open the way to molecular knowledge, allowing precise interpretation of pathology in individual cases followed by finding proper therapy. However, the large-scale improvement of medical efficacy seems to be achieved with the development of screening tests that, being not invasive and cheap, may allow for personal repeatable use and early revealing of threatening diseases.

Słowa kluczowe

EN

individual therapy; personalised medicine; screening test

• Wydawca: Uniwersytet Jagielloński - Collegium Medicum ; Index Copernicus Sp. z o.o.
• Czasopismo: Bio-Algorithms and Med-Systems
• Rocznik: 2019
• Tom: Vol. 15, no. 4
• Strony: art. no. 20190047
• Opis fizyczny: Bibliogr. 50 poz., rys.

Twórcy

autor

Konieczny Leszek

• Department of Medical Biochemistry, Jagiellonian University Medical College, Kopernika 7, 31-034 Krakow, Poland

autor

Roterman Irena

• Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, Lazarza 16, 31-530 Krakow, Poland

Bibliografia

• [1] Garrett WS. The gut microbiota and colon cancer. Science 2019;364:1133-5.
• [2] Donia MS, Fischbach MA. Human microbiota. Small molecules from the human microbiota. Science 2015;349:1254766.
• [3] Cani PD. Gut cell metabolism shapes the microbiome. Science 2017;357:548-9.
• [4] Nobs SP, Elinav E. Walk on the wildling side. Science 2019;365:444-5.
• [5] Rosshart SP, Herz J, Vassallo BG, Hunter A, Wall MK, Badger JH, et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science 2019;365:eaaw4361.
• [6] Bleich RM, Arthur JC. Revealing a microbial carcinogen. Science 2019;363:689-90.
• [7] Muir A, Vander Heiden MG. The nutrient environment affects therapy. Science 2018;360:962-3.
• [8] Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 2018;555:210-5.
• [9] O’Neill C. Gut microbes metabolize Parkinson’s disease drug. Science 2019;364:1030-1.
• [10] Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril 2018;109:952-63.
• [11] Maughan T. The promise and the hype of ‘personalised medicine’. New Bioeth 2017;23:13-20.
• [12] Haigis KM, Cichowski K, Elledge SJ. Tissue-specificity in cancer: the rule, not the exception. Science 2019;363:1150-1.
• [13] Ablain J, Xu M, Rothschild H, Jordan RC, Mito JK, Daniels BH, et al. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Science 2018;362:1055-60.
• [14] Ledford H. Five big mysteries about CRISPR’s origins. Nature 2017;541:280-2.
• [15] Amitai G, Sorek R. Intracellular signaling in CRISPR-Cas defense. Science 2017;357:550-1.
• [16] Zimmermann M, Murina O, Reijns MA, Agathanggelou A, Challis R, Tarnauskaitė Ž, et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 2018;559:285-9.
• [17] Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science 2018;361:866-9.
• [18] Scott A. A CRISPR path to drug discovery. Nature 2018;555:810-1.
• [19] Mosteiro L, Pantoja C, Alcazar N, Marión RM, Chondronasiou D, Rovira M, et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 2016;354:aaf4445.
• [20] Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature 2017;548:413-9.
• [21] Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, et al. The target landscape of clinical kinase drugs. Science 2017;358:eaan4368.
• [22] Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 2018;558:540-6.
• [23] Semple RK, Vanhaesebroeck B. Lessons for cancer drug treatment from tackling a non-cancerous overgrowth syndrome. Nature 2018;558:523-5.
• [24] Konieczny L, Roterman I, Spólnik P. Systems biology. Dordrecht: Springer, 2013.
• [25] Manfredi C, Tindall JM, Hong JS, Sorscher EJ. Making precision medicine personal for cystic fibrosis. Science 2019;365:220-1.
• [26] Sievers QL, Petzold G, Bunker RD, Renneville A, Słabicki M, Liddicoat BJ, et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 2018;362:eaat0572.
• [27] Snyder EY. Finding a new purpose for old drugs. Science 2017;357:869-70.
• [28] Manning BD. Signalling protein protects the heart muscle from pressure-related stress. Nature 2019;566:187-8.
• [29] Ranek MJ, Kokkonen-Simon KM, Chen A, Dunkerly-Eyring BL, Vera MP, Oeing CU, et al. PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress. Nature 2019;566:264-9.
• [30] Servick K. Unexpected drug emerges for stroke recovery. Science 2019;363:805.
• [31] Couzin-Frankel J. Anti-inflammatory prevents heart attacks. Science 2017;357:855.
• [32] Hejtmancik JF. Cataracts dissolved. Nature 2015;523:540-1.
• [33] Couzin-Frankel J. Second chapter. Science 2016;353:983-5.
• [34] Xu M, Pokrovskii M, Ding Y, Yi R, Au C, Harrison OJ, et al. c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 2018;554:373-7.
• [35] Munn LL, Jain RK. Vascular regulation of antitumor immunity. Science 2019;365:544-5.
• [36] McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 2015;523:612-6.
• [37] Clouthier DL, Ohashi PS. Costimulation, a surprising connection for immunotherapy. Science 2017;355:1373-4.
• [38] Bryant VL, Hodgkin PD. Life, death, and antibodies. Science 2017;358:171-2.
• [39] Jagusiak A, Rybarska J, Piekarska B, Stopa B, Konieczny L. Self-assembled molecules - new kind of protein ligands - supramolecular ligands. In: Roterman I, Konieczny L, editor. Springer Open, 2018:21-42.
• [40] Zemanek G, Jagusiak A, Rybarska J, Piwowar P, Chłopaś K, Roterman I. Self-assembled molecules – new kind of protein ligands. In: Roterman I, Springer Open, 2018:43-60.
• [41] Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 2019;567:257-61.
• [42] Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multianalyte blood test. Science 2018;359:926-30.
• [43] Kalinich M, Haber DA. Cancer detection: seeking signals in blood. Science 2018;359:866-7.
• [44] Martinez-Jimenez CP, Eling N, Chen HC, Vallejos CA, Kolodziejczyk AA, Connor F, et al. Aging increases cell-to-cell transcriptional variability upon immune stimulation. Science 2017;355:1433-6.
• [45] Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol 2012;22:R741-52.
• [46] Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Geroscience: linking aging to chronic disease. Cell 2014;159:709-13.
• [47] Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature 2019;571:183-92.
• [48] Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Aging: a common driver of chronic diseases and a target for novel interventions. Cell 2014;159:709-13.
• [49] Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007;117:2033-5.
• [50] Steketee RW, ter Kuile F. Single low-dose primaquine to reduce malaria transmission. Lancet Infect Dis 2014;14:91-2.

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2020).